Health Care & Life Sciences » Pharmaceuticals | Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
54.71 M
Public Float
38.01 M
Intra-Cellular Therapies Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.82
Market Cap
$742.12 M
Shares Outstanding
55.14 M
Public Float
44.17 M

Profile

Address
430 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.intracellulartherapies.com
Updated 07/08/2019
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease.

Financials

View All

Sharon Mates
Chairman, President & Chief Executive Officer
Robert L. van Nostrand
Lead Independent Director